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A B S T R A C T   
Chemokines and their receptors represent a potential target for immunotherapy in chronic inflammation. They 
comprise a large family of cytokines with chemotactic activity, and their cognate receptors are expressed on all 
cells of the body. This network dictates leukocyte recruitment and activation, angiogenesis, cell proliferation and 
maturation. Dysregulation of chemokine and chemokine receptor expression as well as function participates in 
many pathologies including cancer, autoimmune diseases and chronic inflammation. In atherosclerosis, a lipid- 
driven chronic inflammation of middle-sized and large arteries, chemokines and their receptors participates in 
almost all stages of the disease from initiation of fatty streaks to mature atherosclerotic plaque formation. 
Atherosclerosis and its complications are the main driver of mortality and morbidity in cardiovascular diseases 
(CVD). Hence, exploring new fields of therapeutic targeting of atherosclerosis is of key importance. This review 
gives an overview of the recent advances on the role of key chemokines and chemokine receptors in athero-
sclerosis, addresses chemokine-based biomarkers at biochemical, imaging and genetic level in human studies, 
and highlights the clinial trials targeting atherosclerosis.   
1. Introduction 
Atherosclerosis is the primary cause of cardiovascular diseases (CVD) 
and is initiated by endothelial cell (EC) activation through modified 
lipids such as oxidized low-density lipoprotein (ox-LDL) [1,2]. Activated 
ECs release chemokines, which allow for the recruitment of immune 
cells into the subendothelial space called the intima. The recruited 
leukocytes produce inflammatory mediators, thus augmenting the 
ongoing chronic inflammatory process at arterial sites, orchestrating 
monocyte to macrophage differentiation, foam cell formation, migra-
tion, and proliferation of smooth muscle cells (SMCs). As the disease 
progresses, the complex inflammatory milieu leads to rupture of un-
stable lesions and subsequent thrombosis, which might cause severe 
clinical complications [1]. Chemokines participate in almost all the 
stages from initiation of a fatty streak to mature lesion formation, and 
better understanding of their pathophysiological role would be of great 
value to clinical management. Chemokines, are a family of small, 
secreted, and structurally related cytokines with chemotactic properties 
and play a crucial role in inflammation and immunity [3]. 
This review recapitulates the role of key chemokines and chemokine 
receptors in atherosclerotic animal models, discusses advances in using 
chemokines or chemokine receptors as biomarkers or imaging tracers for 
diagnosis and risk stratification in human CVD, overviews genetic al-
terations in genes coding for chemokine and chemokine receptor and 
explores their association with CVD, and summarizes (ongoing) clinical 
trials. 
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1 These authors contributed equally to this manuscript and share first authorship.  
2 These authors contributed equally to this manuscript and share last authorship. 
Contents lists available at ScienceDirect 
Atherosclerosis 
journal homepage: www.elsevier.com/locate/atherosclerosis 
https://doi.org/10.1016/j.atherosclerosis.2021.06.912 
Received 4 March 2021; Received in revised form 7 May 2021; Accepted 24 June 2021   
Atherosclerosis 330 (2021) 95–106
96
2. Chemokines and their receptors in experimental 
atherosclerosis (animal models) - recent insights 
Chemokines and their receptors are multifunctional orchestrators of 
acute and chronic immune responses facilitating for example leukocyte 
mobilization, adhesion, migration, differentiation and homing to 
different tissues. Given the aforementioned immune regulatory prop-
erties, the chemokine (-receptor) network extensively contributes to 
various stages of atherosclerosis, such as leukocyte trafficking and 
infiltration into atherosclerotic lesions, foam cell formation and cell 
maturation within the plaque. In this section, novel findings on the role 
of a list of chemokines and their receptors (Table 1) in atherosclerosis 
will be revealed, highlighting potential new mechanisms which could be 
novel targets for future therapeutic approaches. 
2.1. Chemokines in atherosclerosis 
2.1.1. CCL chemokine ligands 
CCL2 (also known as monocyte chemotactic protein 1 [MCP]-1) is a 
proatherosclerotic chemokine regulating the trafficking of inflammatory 
cells and thereby leukocyte migration into the artery wall [4]. Surpris-
ingly, CCL2 release from myeloid cells was shown to be affected in a 
circadian fashion at different times of the day. Winter et al. showed that 
CCL2 dependent myeloid cell recruitment to atherosclerotic lesions os-
cillates in a diurnal fashion with a peak during the night phase. CCR2 
antagonism at two different times (noon and midnight) in Apolipopro-
tein E deficient (Apoe− /− ) mice fed with western diet (WD) for 4 weeks, 
revealed a significant reduction in plaque size only at midnight 
compared to the vehicle control [5]. Hence, chrono-pharmacological 
targeting of CCL2 mediated signaling could be of therapeutic interest. 
CCL3 (also known as macrophage inflammatory protein 1α) is an 
inflammatory chemokine inducing chemotaxis of different leukocyte 
subsets, including monocytes/macrophages and T-lymphocytes (T cells) 
via CC chemokine receptors (CCR)1, CCR4, or CCR5 [6]. Hematopoietic 
deficiency of CCL3 was shown to significantly reduce aortic sinus lesion 
formation in LDL receptor (LDLR) deficient (Ldlr− /− ) mice after 12 
weeks of WD [7]. In addition, atorvastatin treatment alleviates 
atherosclerotic plaque burden in Apolipoprotein E deficient (Apoe− /− ) 
mice fed a WD for 16 weeks through downregulation of CCL3 expression 
[8]. Taken together, CCL3 seems to be pro-atherogenic. 
CCL5 (also known as RANTES: regulated upon activation, normal T 
cell expressed and secreted) is another important chemokine mediating 
immune cell recruitment and infiltration to the atherosclerotic plaque 
[9]. For example, platelet derived CCL5 and human neutrophil peptide 1 
(HNP1) liaise together to form stable heteromers to facilitate classical 
monocyte recruitment to sites of inflammation. Blocking of this 
HNP1-CCL5 interaction by dose dependent treatment of CX3CR1 re-
porter mice (Apoe− /− Cx3cr1egfp/WT; WD for 4 weeks) with the peptidic 
inhibitor SKY leads to inhibition of HNP1-CCL5 induced adhesion of 
classical monocytes [10]. Antagonizing CCL5-CXCL4 heteromers with 
MKEY, a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer 
formation, significantly reduced neutrophil recruitment as well as 
monocyte infiltration in the infarcted areas of C57BL/6 mice [11]. 
Concluding, blocking CCL5 heteromerization with its various interac-
tion partners could be a promising way to diminish leukocyte recruit-
ment to sites of inflammation. 
CCL17 is mainly expressed by a subset of myeloid dendritic cells 
(DCs) and mediates chemotactic activity of T cells through its receptor 
CCR4. CCL17 deficiency in Apoe− /− mice limited atherosclerotic lesion 
growth, which was ascribed to an enhanced number of regulatory T cells 
(Treg) in the absence of CCL17 [12]. Moreover, nuclear magnetic 
resonance spectroscopy revealed heteromeric interaction of CCL17 and 
CCL5. Inhibition of these heterodimers by a specific peptide (CAN) in 
Apoe− /− mice fed WD for 6 weeks leads to reduction in lesion size in the 
aortic root underlining the proatherogenic role of CCL17 [13]. 
In-vivo studies in BALB/C mice suggest selective expression of CCL19 
by mature DCs [14]. Higher expression of CCL19/CCL21 was observed 
within the atherosclerotic plaques in aortae of Apoe− /− mice, also in 
regions with predominantly CD68+ macrophages and in areas rich in 
CD3+ T cells. In the same study, in-vitro experiments suggest involve-
ment of CCL19 and especially CCL21 in increasing the release of in-
flammatory cytokines and enhance matrix metalloproteinase (MMP) 
activity in THP-1 derived macrophages [15]. In conclusion, this study 
emphasized the increased CCL19 and CCL21 levels in atherosclerosis 
and how the dysfunction in their regulation could lead to altered re-
sponses in T cells and macrophages. This leads to reduced plaque sta-
bility and helps atheroprogression. Contrary to this study, in an in-vivo 
study including transplantation of bone marrow from plt/plt mice, which 
lack the expression of CCL19 and CCL21-Ser, into irradiated Ldlr− /−
mice lead to significant upregulation of leukocyte recruitment into the 
atherosclerotic plaques. This indicates that reduced expression of CCL19 
and CCL21 in plt/plt/Ldlr− /− leads to reduced pro-inflammatory acti-
vation and higher plaque stability. Additionally, in the same study 
downregulation of CCL19 reduced the uptake of oxLDL in the lesion 
macrophages of plt/plt/Ldlr− /− mice thereby resulting in smaller lesion 
macrophages and it was accompanied by increased plaque stability [16]. 
These findings suggest the contradictory role of CCL19 and CCL21 in 
atherosclerosis and further in-vivo studies are needed to unravel their 
exact immune-regulatory role in atherogenesis and plaque stability. 
2.1.2. CXC chemokine ligands 
CXC chemokine ligands like CXCL1, CXCL2, CXCL4, CXCL12 and 
CXCL16 play various roles in the progression of atherosclerosis. ECs 
release CXCL1 upon accumulation of oxLDL-induced lysophosphatidic 
acid and high levels of CXCL1 lead to recruitment and migration of 
leukocytes to the carotid bifurcation, while depletion of CXCL1 reduces 
macrophage accumulation and reduces atherosclerotic progression 
[17]. Evasin-3, a pharmacological inhibitor of CXCL1 and CXCL2, 
fostered reduction of MMP-9 and intraplaque neutrophil recruitment in 
Apoe− /− mice (fed WD for on 11 weeks and cast placement at week 2) 
[18]. Inhibition of CXCL1 in Apoe− /− mice (fed WD for 4 weeks) with 
infusion of an antibody to mCXCL1 led to reduced lesion area, and 
decline of monocyte and macrophage expansion [19]. In addition, 
Table 1 







CCL3 CCR1, CCR4, CCR5 






CXCL4 CCR1, CXCR3 
CXCL12 CXCR4, CXCR7 





CCR1 CCL7, CCL13, CCL3, CCL5, CCL23, CCL14, CCL15, CXCL4, 
CCL16 
CCR2 CCL2, CCL7, CCL8, CCL12 (mouse only), CCL13, 
CCL16 (human only) 
CCR5 CCL3, CCL4, CCL5, CCL8 
CCR7 CCL19, CCL21 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR4 CXCL12, CCR5 
CXCR6 CXCL16 
CX3CR1 CX3CL1  
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CXCL4, a platelet-derived chemokine, interacts with CCL5 to make 
stable heterodimers, amplifying monocyte and neutrophil recruitment, 
as well as neutrophil extracellular trap formation. Inhibition of this 
interaction was shown to inhibit atherosclerosis in mice [11,20]. 
CXCL12, also known as stromal cell derived factor 1 (SDF-1) alpha, 
and its receptor CXCR4 are involved in the healing of injured or ischemic 
vascular tissue. One study suggested an atheroprotective role of CXCL12 
in Apoe− /− mice by recruitment of SMC progenitor cells [21]. Here, 
CXCL12 contributes to stabilization of atherosclerotic plaques by 
inducing fibrous cap thickening and SMC progenitor cell recruitment to 
the plaque [22]. However, another recent study evaluated the role of cell 
specific CXCL12 depletion using ubiquitous knockout, SMC knockout, 
hematopoietic knockout, non-hematopoietic knockout and endothelial 
cell specific knockout mice on Apoe− /− background. In this study, 
EC-specific CXCL12 deficiency in Apoe− /− mice implies an atheroprog-
ressive role of CXCL12 when of endothelial/resident cellular origin [23]. 
Therefore, source and context of CXCL12 release have a crucial impact 
on its role in vascular inflammation. 
Unlike other chemokines, CXCL16 contains mucin stalk, trans-
membrane and cytoplasmic domains. It can be present as membrane 
bound or as a soluble form and is expressed on activated T cells and 
natural killer T cells [24]. The soluble form is linked to the migration of 
T cells to atherosclerotic plaques. Cxcl16− /− Ldlr− /− mice showed an 
increased number of macrophages in aortic arches and increased 
atherosclerosis lesion size compared to control animals [25]. In an in 
vivo study, overexpression of circulatory CXCL16 induced by intrave-
nous injection of a lentiviral vector carrying CXCL16 transgene into 
Apoe− /− mice promoted a vulnerable plaque phenotype (59% higher 
plaque vulnerability) compared to control mice [26]. Together these 
data suggest a pro-atherosclerotic role of soluble CXCL16. 
Extensive studies on key chemokine ligands like CCL2, CCL3, CCL5, 
CCL17, CXCL1, CXCL2, CXCL4, CXCL12 and CXCL16 suggest their role 
in atherosclerosis and pave the way for the therapeutic targeting of 
chemokines in atherosclerosis. The studies involving targeting of che-
mokine ligands in a circadian fashion were missing until Winter et al. 
explored the chrono-pharmacological targeting of CCL2 in early stages 
of atherosclerosis. The authors detected the substantial localization of 
immobilized CCL2 on carotid endothelium covering atherosclerotic le-
sions and at sites, with rhythmic myeloid cell adhesion in hyper-
cholesteremic mice. On the transcriptional level, high Ccl2 expression in 
circulating monocytes and neutrophils lead to high levels of CCL2 in 
plasma especially at early morning hours. Additionally, time and site 
dependent in-vivo analyses of myeloid cell adhesion to the carotid 
endothelium and to the cremasteric microcirculation showed high 
leukocyte adhesion at morning in carotid endothelium as compared to 
microcirculation. Additionally, at early morning, disruption of CCL2 
signaling lead to reduced adhesion of myeloid cells to carotid endo-
thelium of hypercholesteremic Cx3cr1GFP/WTApoe− /- mice. Contrary to 
this, at the same time, CCR2 inhibition had no effect on cell adhesion in 
the cremasteric microcirculation. This study provides a novel targeting 
approach of a time- and site-specific inhibition of CCL2 at early stages of 
atherosclerosis. However, it would be interesting to perform such a 
targeting strategy during later stages of atherosclerosis and to investi-
gate if the other organs also have the similar differences in micro and 
macro-circulation. 
2.2. Roles of chemokine receptors in atherosclerosis 
Functional effects of chemokines are mediated by their binding to 
their (corresponding) cell surface receptors, and the ligand repertoire of 
chemokine receptors is typically class restricted. Therefore, we would 
summarize the advances of three important classes of the receptors: CC, 
CXC and CX3C chemokine receptors. In addition, the majority of re-
ceptors are able to interact with many different ligands of the same class 
and ligands as well as receptors may also form heteromers, rendering the 
chemokine ligand-receptor network multifaceted and promiscuous. 
Thus, it is not surprising that ligand and receptor responses may differ 
depending on ligand or receptor availability, which are also reliant on 
the type of inflammation present. Hence, this network promiscuity in 
the context of a chronic inflammation like atherosclerosis increases the 
complexity of identifying therapeutic targets. 
2.2.1. CC chemokine receptors 
CCR1 has a detrimental role in atherogenesis by mediating monocyte 
recruitment, as evident by a reduced number of classical monocytes in 
aortas in Ccr1− /− Apoe− /− mice both after 4 weeks and 8 weeks of WD 
[19]. However, transplantation of Ccr1− /− bone marrow into Ldlr− /−
mice unveiled an increased lesion size and higher macrophage and T cell 
accumulation at sites of inflammation after exposure to a high choles-
terol diet for 12 weeks compared to Ccr1+/+ bone marrow recipients 
[27]. The complexity of hematopoietic cells and different mouse strains 
might be responsible for the different roles of CCR1 in atherosclerosis. 
Cell specific deletion of CCR1 would be necessary to uncover this 
discrepancy. 
CCR2, receptor for CCL2, mediates monocyte chemotaxis. CCR2- 
targeted siRNA treatment in Apoe− /− mice reduced recruitment of Ly- 
6C (high) monocytes, attenuated infarct inflammation, and curbed 
post-myocardial infarction left ventricular remodeling [28]. Apoe− /−
mice treated with the CCR2 antagonist (15a) exhibited a reduced 
number of circulating CCR2+ monocytes and atherosclerotic burden in 
aortic roots after 6 weeks WD [29]. As aforementioned, blockade of 
CCR2-CCL2 signaling abolished oscillatory leukocyte adhesion and 
timed pharmacological CCR2 neutralization during the activity phase 
resulting in reduced atherogenesis without disturbing microvascular 
recruitment [5]. Hence, CCR2-based therapy would be of great potential 
to treat atherosclerosis. 
CCR5 exerts an atherogenic phenotype as apparent from mice lack-
ing CCR5. CCR5 deficiency resulted in less lesional macrophages in diet- 
induced atherosclerosis, and neointima formation was reduced in an 
IL10-dependent manner [30,31]. Recently, CCR5 blockade by mar-
aviroc, a negative allosteric modulator of CCR5, was also demonstrated 
to hinder enhanced recruitment in MT4-MMP (membrane type-4 matrix 
metalloproteinase, also named MMP17)-deficient Ly6Clow monocytes to 
early atherosclerotic lesions in MT4-MMP− /− bone marrow transplanted 
Ldlr− /- recipients fed on WD for 8 weeks [32]. 
CCR7 is identified to regulate T cell homeostasis and stimulate DC 
maturation. Deletion of CCR7 in Apoe− /− mice led to increased plaque 
burden by increasing T cell content in atherosclerotic lesions after WD 
for 8 weeks, and transplantation of Ccr7− /− Apoe− /− bone marrow into 
Ccr7+/+Apoe− /− mice followed by a WD for 8 weeks resulted in 
increased lesion size [33]. In contrast, CCR7 deficiency was reported to 
attenuate plaque burden in Ldlr− /− mice after 12 weeks of WD. More-
over, transfer of CCR7+/+ T cells primed with oxLDL-pulsed DCs into 
Ccr7− /− Ldlr− /− recipient mice fed a WD for 12 weeks revealed an 
increased atherosclerosis plaque burden to an extent comparable to 
Ldlr− /− mice [34]. This discrepancy might be attributable to the com-
plex role of CCR7 signaling in different animal strains in the context of 
atherosclerosis. Cell-specific CCR7 knockout mice would be important 
to fully address the role of this receptor in T cells/macrophages/DC 
homing and T-cell development/activation under atherogenic 
conditions. 
2.2.2. CXC and CX3C chemokine receptors 
CXCR2 is known for its function in neutrophil mobilization and 
participates in early atherosclerotic lesion formation [35,36]. More 
recently, a macrophage migration inhibitory factor (MIF) -derived 
cyclopeptide was described to inhibit key inflammatory and atherogenic 
MIF activities through interaction with CXCR2 [37]. All the above 
findings are indicative of a pro-atherogenic role of CXCR2. On the other 
hand, CXCR2 activation by its ligand CXCL5 has been described to in-
crease cholesterol efflux in macrophages via upregulation of ABCA1, 
thus playing a protective role in atherogenesis by limiting foam cell 
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formation [38]. Hence, the selective blockade of CXCR2/MIF interaction 
while keeping the CXCR2/CXCL5 interaction intact would be of 
importance in CXCR2-targeted therapy against atherosclerosis. 
The chemokine receptor CXCR4 is a key regulator of cell homeostasis 
and seems to have atheroprotective functions. Recent studies showed 
that B-cell-specific knockout of CXCR4 in mice reduces bone marrow 
IgM production and plasma IgM levels, an effect which could be restored 
by the overexpression of CXCR4 [39,40]. Moreover, vascular CXCR4 
suppresses atherosclerosis by sustaining endothelial barrier function 
through WNT/β-catenin signaling, and supporting a contractile SMC 
phenotype [41]. The longevity-associated variant (LAV) of the 
bactericidal/permeability-increasing fold-containing family B member 4 
(BPIFB4) has been found significantly enriched in long-living individual 
and its transfer was shown to limit atherosclerosis and skewed macro-
phages towards an M2-resolving phenotype through modulation of 
CXCR4 [42]. However, CXCR4/MIF interactions were described to 
mediate atherogenesis. The dual effect of CXCR4 has hampered the 
therapeutic application of CXCR4 agonist/antagonist in the treatment of 
atherosclerosis. Inspiringly, a soluble CXCR4 ectodomain mimics 
(msR4M-L1) was designed and has been proved to exhibite high affinity 
to MIF, with no binding to CXCL12. Fluorescence polarization and 
microscale thermophoresis in a binding-competition approach also 
confirmed an intact cardioprotective axis of MIF/CD74 in the presence 
of msR4M-L1. Next, the MIF/msR4M-L1 core binding region was map-
ped and the complex formation was verified using alanine mutants of 
both msR4M-L1 and MIF. The selective msR4M-L1/MIF binding was 
then specially blocked MIF/CXCR4-driven cell signaling response 
without any interference of CXCL12/CXCR4-elicited signaling in a yeast 
system that expresses human CXCR4. Moreover, HEK293-CD74 trans-
fectant data showed that msR4M-L1did not affect the MIF binding to 
cell-surface CD74. In this study, msR4M-L1 dose-dependently inhibited 
MIF-triggered uptake of fluorescently labeled oxidized low-density li-
poprotein and motility of human monocytes. Monocyte adhesion on 
human aortic endothelial was also inhibited by msR4M-L1 both under 
static condition and shear stress. In addition, msR4M-L1 localized to 
atherosclerotic plaques in a MIF-specific manner and inhibited 
MIF-mediated atherogenic leukocyte recruitment ex vivo. Apoe− /− mice 
receiving msR4M-L1 in parallel to HFD for 4.5 weeks exhibited reduced 
plaque burden, lesional macrophage accumulation and reduction of 
multiple inflammatory cytokines in the circulation [43]. Given the fact 
that chemokine ligand-receptor network promiscuity has been obstacle 
for chemokine ligands (receptors) as therapeutic targets in clinical 
application, the engineered chemokine-selective- GPCR-ectodo-
main-based mimicry principle that distinguishes disease-exacerbating 
from -protective signaling in this study would raise more attention to 
the chemokine-based strategy and could be of great potential for the 
treatment or prevention of other inflammatory diseases. 
CXCR6 is reported to promote T cell homing, interferon-gamma 
production, and macrophage accumulation into the aortic wall and 
mice lacking CXCR6 on Apoe− /- background had reduced atherosclerosis 
compared to Apoe− /- controls after WD for 17 weeks or chow diet for 56 
weeks [44]. CXCR6 was also shown to accelerate foam cell formation in 
atherosclerosis and regulates the recruitment of pro-inflammatory IL-17 
A-producing T cells into atherosclerotic aortas [45,46]. Together these 
data suggest a pro-atherosclerotic role of CXCR6. 
CX3CR1 activation plays a crucial role in recruitment, stimulation 
and the survival of monocytes/macrophages in the pathogenesis of 
atherosclerosis. DC-restricted antigen-uptake receptor (DEC205) tar-
geted DNA vaccine against CX3CR1 protects against atherogenesis in 34 
week old Apoe− /− mice fed on chow diet [47]. Further, designed VHH 
(variable domains of camelid heavy chain-only) antibodies to overcome 
the failure in antagonistic monoclonal antibodies to CX3CR1, have 
recently been shown to block the CX3CR1 receptor in vivo and 
concomitantly reduced the progression of atherosclerosis in Apoe− /- 
mice fed WD for 16 weeks [48]. Since the presence of its unique ligand 
CX3CL1 (fractalkine) was confirmed in aorta of Ldlr− /− mice, 
engineered Treg overexpressing CX3CR1 were generated to guide Treg 
selectively to the plaque. In line, adoptive transfer of CX3CR1+Tregs in 
Ldlr− /− mice resulted in reduced plaque progression and lipid deposition 
and ameliorated plaque stability [49]. Adoptive cell therapy to enhance 
immuno-suppressive functions specifically at sites of vascular inflam-
mation are a promising therapeutic approach to limit atherosclerosis 
progression. 
3. Chemokines in diagnosis and disease severity in human 
atherosclerosis 
3.1. Chemokine and chemokine receptor expression in human 
atherosclerosis 
There is a growing body of evidence describing genes altered at the 
onset or at advanced stages of atherogenesis. Analytical tools that are 
available today (e.g. gene expression microarrays or RNA sequencing) 
allow for the detection of the alteration in gene expression of every 
single known gene in the atherogenic process. Taking advantage of 
publicly available datasets, we searched the atherosclerosis related 
datasets with a sample size of more than ten in each group to diminish 
the false positive rate from limited sample sizes (except for one dataset 
of five patients with familial hypercholesterolemia) in the Gene 
Expression Omnibus repository. Thereafter we compared the gene 
expression of chemokines and chemokine receptors described above in 
human plaque specimens or blood samples versus corresponding controls 
(results are summarized in Fig. 1 and Table 2), thus providing infor-
mation on how the chemokine network differs in atherosclerotic tissues 
from control samples. 
It should be noted that different studies have not always produced a 
consistent outcome. For example, CCL2 and CCR2 were higher 
expressed in atheroma plaques compared to distant macroscopically 
intact tissue from the same patient (Accession number: GSE43292 [50]), 
but the expression of CCL2 or CCR2 did not differ between atheroscle-
rotic arterial wall and distal part of mammary artery as 
non-atherosclerotic arterial wall (GSE40231 [51]). The latter is likely to 
be attributed to temporal expression differences of some chemokines 
during different stages of atherogenesis. For instance, multiple chemo-
kines (CCL3, CCL5, CCL19, CCL21, CXCL12, CXCL16) and chemokine 
receptors (CCR1, CCR2, CCR5, CCR7, CXCR4, CX3CR1) were enhanced 
in advanced atherosclerotic plaques versus early-stage lesions 
(GSE28829 [52]). However, we did not observe any differences in pe-
ripheral blood mononuclear cell (PBMC) samples from obstructive cor-
onary artery disease compared to non-obstructive coronary artery 
disease in terms of chemokine or receptors expression in GSE90074 
[53]. In addition, chemokines and receptors did not differ in peripheral 
blood samples from atherosclerosis and non-atherosclerosis subjects 
with larger sample size in GSE20129 [54]. These findings might suggest 
a more plaque-relevant chemokine or chemokine receptors alterations 
during atherogenesis. Familial hypercholesterolemia (FH) patients 
exhibited higher CCR7 in blood compared to control subjects in 
GSE13985 (no publication available). Overall, CCL5, CCL19 and CXCR4 
were higher in plaque specimens compared to control tissue or higher in 
advanced atherosclerotic plaques versus early-stage plaque. Taken 
together these gene expression analysis reveals interesting and signifi-
cant changes of chemokine and chemokine receptor expression in pla-
que and blood samples of human origin. However, association does not 
necessarily mirror causality and hence has still to be accompanied by 
mechanistic studies linking cause and consequence. 
3.2. Biomarkers and imaging tools for diagnosis and prognosis 
Identification of biomarkers correlating with the disease severity of 
coronary artery disease (CAD) has led to important advances in pre-
vention and treatment. As chemokines participate in the initiation and 
development of atherosclerosis, their titers are frequently used as 
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biomarkers for diagnosis and prognosis in CAD patients (Table 3). 
Hypercholesterolemia is one of the risk factors for CVD. Notably, for 
the population with hypercholesterolemia in the absence of CAD, Ral-
lidis et al. revealed that simvastatin significantly decreases CCL2 levels 
in these patients, suggesting that CCL2 is a sensitive marker to detect the 
anti-inflammatory effects of simvastatin in blood, especially for early 
stages of atherosclerosis [55]. In addition, there was a postprandial 
decrease in chemokines (CCL2, CCL3, CCL4) related to early athero-
sclerotic processes after an oral unsaturated fat load tested in familial 
hypercholesterolemia patients, while no alteration in chemokine levels 
was observed in normolipidemic controls [56]. In addition, elevated 
levels of chemokine CCL5 in patients with stable angina pectoris may 
also identify patients prone to plaque formation and atherosclerosis 
[57]. 
Chemokines are also used to assess the disease severity in ongoing 
coronary heart disease. Elevated baseline levels of CCL2 were associated 
with both traditional risk factors for atherosclerosis and an increased 
risk for clinical adverse events (death or myocardial infarction) in a 
large cohort of patients with acute coronary syndromes [58]. In addi-
tion, circulating CCL2 levels with a cut-off of 61.95 pg/mL had 91% 
sensitivity and 91% specificity for predicting CAD patients. Combined 
analysis of CCL2 with IL-6 levels predicts higher mortality in CAD pa-
tients with high sensitivity and specificity and could provide more in-
formation for clinical management [59]. Plasma CCL5 levels have also 
been reported to correlate with cardio-cerebral atherosclerosis burden 
in patients with ischemic cerebrovascular disease [60]. Serum CCL17 
levels were shown to be positively associated with the type and severity 
of CAD independently of traditional cardiovascular risk factors [61] 
Fig. 1. Expressions of chemokines and chemokine receptors in plaque tissues or blood from human atherosclerosis related GEO datasets. 
Heatmap generated from (A) 32 atheroma plaques (Plaque) and 32 distant macroscopically intact tissue (Con) from the same patient in GSE43292; (B) 40 
atherosclerotic arterial walls (AAW) and 40 non-atherosclerotic arterial walls (Con, distal part of mammary artery) in GSE40231; (C) 16 advanced atherosclerotic 
plaques (Advanced) and 13 early-stage (Early) plaques in GSE28829; (D) 93 obstructive coronary artery disease (obsCAD) and 50 non-obstructive coronary artery 
disease (non_obsCAD) PBMC samples in GSE90074; (E) 48 atherosclerosis (AS) and 71 non-atherosclerosis (Con) peripheral blood samples from the Multi-Ethnic 
Study of Atherosclerosis cohort in GSE20129. (F) Blood collected from 5 patients diagnosed with familial hypercholesterolemia (FH) and 5 controls subjects in 
GSE13985. Differentially expressed genes were obtained by limma package in R. Genes with a fold change >1.2 or <0.8 and adjusted p value < 0.05 versus control 
group in heatmap are denoted with a red asterisk. 
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while CXCL12 could serve as an independent predictor of death or re-
petitive acute myocardial infarction and new-onset heart failure [62]. In 
patients with acute coronary syndrome, CXCL16 levels at admission are 
independently related to adverse clinical outcomes, especially cardio-
vascular death, indicating that CXCL16 levels are beneficial for risk 
stratification under these conditions [63]. 
As the plaque continues to develop it may become unstable and 
rupture. At the advanced or unstable stage, biomarkers to assess the 
disease severity or predict clinical outcome are of essential importance 
for disease monitoring. Kraaijeveld et al. revealed CCL5 and CCL18 titers 
to be significantly elevated in patients with refractory unstable angina 
pectoris compared to stabilized patients, hence combined measurement 
of CCL5 and CCL18 may predict future cardiovascular adverse events 
[64]. Similarly, CCL18 serum levels correlate with coronary calcifica-
tion and segment involvement score, and CCL5 demonstrates an inde-
pendent association with the presence of obstructive CAD, as well as the 
occurrence of primary cardiac events [65]. Higher levels of CCL2, CCL5 
and CX3CL1 are found in acute myocardial infarction and unstable 
angina pectoris patients [66]. In addition, CX3CL1 levels are elevated 
the first 12 h after percutaneous coronary intervention in patients with 
acute myocardial infarction [67]. Enhanced CCL19 titers were also 
considered to be a biomarker for identifying high-risk patients in which 
more urgent intervention may be indicated [68]. 
Restenosis after percutaneous coronary intervention is still a major 
clinical problem. Platelet, leukocytes and EC activation due to the pro-
cedure are recognized as possible inflammatory triggers fostering 
restenosis [69,70]. The increase of CCL5 might represent a sign of 
restenosis after percutaneous coronary intervention in patients with 
stable angina pectoris [71]. CCL2 plasma levels measured 15 days after 
percutaneous transluminal coronary angioplasty were also described as 
an independent predictor of restenosis [70]. 
Moreover, chemokines are also gaining attention as novel imaging 
tracers to elucidate biological mechanisms. For example, 68Ga-Pentix-
afor, a specific CXCR4 ligand, has been used in motion-corrected tar-
geted positron emission tomography (PET)/computed tomography (CT) 
to enable in vivo characterization of CXCR4 expression in small culprit 
and non-culprit coronary atherosclerotic lesions after acute myocardial 
infarction [72]. Further, arterial wall 68Ga-pentixafor uptake was 
described to be associated with cardiovascular risk factors and calcified 
plaque burden [73], which may hold promise for identification of 
vulnerable plaques. Recently, a pilot study revealed that 
CXCR4-directed 68Ga-Pentixa for PET/CT identified more lesions than 
18F-FDG PET/CT [74]. In addition, 111In-DOTA-DAPTA (CCR5 antago-
nist) has been shown to detect atherosclerotic lesions in Apoe− /− mice, 
suggesting that 111In-DOTA-DAPTA can specifically target CCR5 in 
atherosclerotic lesions [75]. 
All these findings suggest that chemokines and chemokine like mi-
metics may be useful to assess individual atherosclerotic burden, as a 
surrogate marker for CAD screening or a predictor of clinical cardio-
vascular events and may function as imaging tracers for a better un-
derstanding of characteristics of atherosclerotic lesions. 
3.3. Association of single-nucleotide polymorphisms (SNPs) in chemokine 
genes with atherosclerosis 
SNPs occur within a gene or in a regulatory region near a gene and 
may play a direct role in disease pathology by directly affecting gene 
function. Table 4 gives a brief overview of SNPs associated with che-
mokine function in atherosclerosis, which we will describe in more 
detail in the following paragraphs. 
Vascular CXCR4 has been shown to preserve endothelial barrier 
function, and maintains a contractile SMC phenotype in a mouse model 
of diet induced atherosclerosis while the C-allele of SNP rs2322864 in 
the human CXCR4 gene results in decreased CXCR4 expression and is 
Table 2 
Alteration of genes encoding chemokine ligands (receptors) in human atherosclerosis.  
Data set Sample description Changes 
GSE43292 32 atheroma plaques vs. 32 distant macroscopically intact tissues Increased: CCL2, CCL3, CCL5, CCL19, CCL21, CXCL1, CXCL16, CCR1, CCR2, CCR5, 
CCR7, CXCR4, CX3CR1 
GSE40231 40 atherosclerotic arterial walls vs. 40 non-atherosclerotic arterial walls Increased: CCL5, CCL19, CXCR4 
GSE28829 16 advanced atherosclerotic plaques vs. 13 early-stage plaques Increased: CCL3, CCL5, CCL19, CCL21, CXCL12, CXCL16, CCR1, CCR2, CCR5, CCR7, 
CXCR4, CX3CR1 
GSE90074 PBMCs from 93 obstructive coronary artery disease vs. 50 non-obstructive 
coronary artery disease 
No significance changes 
GSE20129 PBMCs from 48 atherosclerosis vs. 71 non-atherosclerosis No significance changes 
GSE13985 Blood from 5 patients with familial hypercholesterolemia vs. 5 controls Increased: CCR7  
Table 3 
An overview of current biomarkers in cardiovascular disease.  
Biomarker Clinical condition Clinical significance 
CCL2 Early stage of AS Simvastatin significantly decreases CCL2 levels in hypercholesterolemia 
Postprandial decrease in CCL2 after an oral unsaturated fat load tested in FH  
CAD Increased risk for clinical adverse events predicting CAD 
Higher in AMI and unstable angina pectoris 
Predictor of restenosis after percutaneous transluminal coronary angioplasty 
CCL3 Early stage of AS Postprandial decrease in CCL3 after an oral unsaturated fat load tested in FH 
CCL4 Early stage of AS Postprandial decrease in CCL4 after an oral unsaturated fat load tested in FH 
CCL5 Stable angina pectoris Patients with elevated CCL5 prone to AS increase of CCL5 might represent a sign of restenosis  
Refractory unstable angina pectoris Predictor of clinical adverse events 
Higher in AMI and unstable angina pectoris 
CCL17 CAD positively associated with the type and severity of CAD 
CXCL12 AMI Predictor of clinical adverse events 
CXCL16 ACS Predictor of clinical adverse events 
CCL18 Refractory unstable angina pectoris Predictor of clinical adverse events 
CX3CL1 CAD Higher in AMI and unstable angina pectoris elevated early after PCI 
AS: atherosclerosis; FH: familial hypercholesterolemia; CAD: coronary artery disease; AMI: acute myocardial infarction; ACS: acute coronary syndrome; PCI: percu-
taneous coronary intervention. 
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associated with increased risk for CAD [41]. Another study showed 
similar results that C-allele of SNP rs2322864 and A-allele of SNP 
rs2228014 were associated with increased risk of CAD [76]. 
Monocytes play a critical role in atherosclerosis and express CX3CR1, 
which acts as either a monocyte chemokine receptor or an adhesion 
molecule and is highly expressed also in foam cells and coronary artery 
SMCs in human atherosclerotic arteries, but not in normal human 
arterial tissue [77]. Evidence shows that two SNPs, in the CXCR1 gene, 
namely rs3732379 (V249I) and rs3732378 (T280 M), were associated 
with a decreased risk of atherosclerosis [78]. In retrospective studies, 
these CX3CR1 polymorphisms have consistently been associated with 
reduced prevalence of atherosclerotic disease endpoints, including ce-
rebrovascular disease [79] and restenosis after coronary stenting [80], 
which is in line with a meta-analysis with pooled data retrieved from 
seven case-control studies unveiling the association of CX3CR1 poly-
morphisms with individual’s susceptibility to CAD [81]. The protective 
role of a methionine at position 280 (280 M) might contribute to a 
reduced and delayed binding of CX3CL1 to the CX3CR1 receptor and 
decreased CX3CL1-induced chemotaxis [82]. As another monocyte 
biology related genetic polymorphism rs1024611 in the promoter region 
of the CCL2 gene (− 2578 A > G) results in greater production of CCL2 
protein and is associated with an excess risk of coronary atherosclerosis 
in an asymptomatic population [83]. Similarly, G-allele of CCL2 (− 2518 
A > G) is also associated with increased risk of CAD in the population of 
patients from the Indian state Punjab [84]. Furthermore, a randomized, 
double-blind, placebo-controlled study demonstrates that patients with 
G allele of rs1024611 (− 2518 A > G) in CCL2 had significantly greater 
reductions in high-sensitivity C-reactive protein levels after CCR2 
blockade, suggesting CCR2 blockade might be tailored and beneficial for 
subsets of CAD patients with G allele at this SNP locus against athero-
sclerosis [85]. 
As the CCL5-CCR5 axis is pivotal to leukocyte recruitment several 
studies also worked on the association of CCL5 or CCR5 polymorphisms 
with atherosclerosis. The SNP rs2107538 (− 403C > T) in the CCL5 gene 
with T allele may increase genetic susceptibility of CAD. The frequencies 
of SNP rs1799987 in CCR5 (CCR5-59029) with GG or GA genotype were 
higher than AA genotype in acute coronary syndrome individuals [86]. 
CCR5 Δ32 (rs333) allele has been linked with higher high-density li-
poprotein, lower triglycerides, lower C-reactive protein levels, 
decreased intima-media thickness, and cardiovascular disease risk [87, 
88]. These SNPs may be incorporated to genotype score and provide a 
prognostic value to cardiovascular clinical events. 
Evidence has demonstrated that the up-regulation of Th1- and Th17 
cell-associated inflammatory responses and down-regulation of anti- 
inflammatory responses of Treg-/Th2 cell-related chemokines was 
associated with CVD [89]. For example, CXCL10 binds to its receptor 
CXCR3 and mainly acts as a chemoattractant for Th1 lymphocytes [90], 
while CCL20 attracts CCR6-expressing Th17 cells [91] and CCL22 or-
chestrates Th2- and Treg migration via its receptor CCR4 [92]. Evidence 
shows that ischemic heart disease patients exhibited a higher frequency 
of the GG genotype at SNP rs4508917 in the CXCL10 gene, whereas the 
same patients have a lower frequency of the AA genotype at SNP 
rs4359426 in the CCL22 gene compared to healthy subjects. However, 
no differences were observed between subjects with different genotypes 
at these two SNP loci with respect to the related serum levels of each 
chemokine, which does not exclude functional differences of the gene 
product [93]. 
As mentioned, CCL17 was shown to be an independent risk factor for 
CAD. The same research group further identified the SNPs rs223899 and 
rs223828 in the CCL17 gene to be significantly associated with CAD 
after adjustment of traditional risk factors of CAD in a Chinese cohort. 
The T allele of rs223828 was shown to be associated with serum CCL17 
concentrations and functional assays further displayed an enhanced 
CCL17 promoter activity in individuals with the T allele of rs223828 
compared to the major allele C in at the CCL17 locus [94]. These findings 
indicate that rs223828 is a functional SNP and the corresponding in-
crease of serum CCL17 enables its atherogenic effects by restraint of Treg 
maintenance and enhancement of platelet aggregation in coagulation 
[95]. 
Taken together, epidemiological analyses have identified many 
biomarker-CAD relationships, however, whether they are truly indica-
tive of a causal association is unknown. Mendelian randomization (MR) 
is a method of using measured variation in genes of known function to 
examine the causal effect of a modifiable exposure (eg. biomarker) on 
disease direction in observational studies. Recently, 237 CAD-associated 
biomarkers and suggested deleterious effects of the SNPs rs880175 and 
rs1482478 in the CXCL12 gene on CAD (odds ratio = 1.69). These two 
SNPs were positively correlated with CXCL12 serum levels in the 
CARDIoGRAM consortium data and MR results were corroborated using 
genetically predicted biomarker levels in the validation cohort of UK 
Biobank. Hence, genetically elevated CXCL12 were associated with an 
increased risk of CAD in the target and validation cohort [96]. Under-
standing the mechanism by which these markers mediate CAD will 
provide novel insights into CAD and could lead to new approaches to 
prevention. 
Although the increment of genome-wide association studies pro-
vided the chance to examine the association of numerous SNPs with 
CAD. However, the studies on the characteristics of the variants on the 
basis of their nature and more in-depth associative studies are quite 
sparse and required at the current era. 
Computational methods would be of great aid in identification of 
change in structure, capacity and strength of proteins as a result of some 
Table 4 
Association of SNPs in chemokines or chemokine receptors with atherosclerosis.  
SNP Gene Role in atherosclerosis PMID 
rs2322864 CXCR4 C allele is associated with increased risk for coronary heart disease 28450349 
rs2228014 CXCR4 A allele is associated with increased risk for coronary heart disease 29581828 
rs3732379 CX3CR1 249I allele is associated with decreased risk for atherosclerosis; an elevated risk of restenosis after stenting. 22731642, 16411 
402 




rs1024611 CCL2 G allele results in greater production of MCP-1; is associated with increased risk of coronary atherosclerosis in an asymptomatic 




rs2107538 CCL5 T allele may increase genetic susceptibility of CAD 26688689 
rs1799987 CCL5 Higher frequency of GG or GA genotype in acute coronary syndrome individuals than AA genotype 26688689 
rs333 CCL5 Δ32 is associated with decreased risk for cardiovascular disease 18436884 
rs4508917 CXCL10 Higher frequency of the GG genotype in ischemic heart disease patients 27152707 
rs4359426 CCL22 Lower frequency of the AA genotype in ischemic heart disease patients 27152707 
rs223828 CCL17 T allele is associated with increased CCL17 promoter activity and increased risk for CAD 28794385 
rs223899 CCL17 T allele is associated with increased risk for CAD 28794385 
rs880175 CXCL12 T allele is associated with increased risk for CAD 30012324 
rs1482478 CXCL12 A allele is associated with increased risk for CAD 30012324  
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variation to segregate between the neutral (harmless) SNPs and SNPs of 
functional importance [97]. Protein-ligand docking would be good 
choice to observe the structural variance in interacting behaviors of 
native and mutants [98]. Therefore, the effect of SNPs on protein 
structure behavior in CAD would provide more information to identify 
and predict pathogenic SNPs and warrant more investigation in future 
studies. 
4. Treatment targeting chemokines in atherosclerosis 
4.1. Pre-clinical studies targeting chemokines and their receptors 
Various preclinical (mouse) studies suggest that targeting chemo-
kines e.g. by small peptide-based constructs could interfere with 
atherosclerosis progression. Targeting of CCL2, CCL5, CCL8 and CXCL9 
via miR-146a/-181b was shown to reduce monocyte adhesion to ECs 
thereby reducing atherosclerosis [99] and disrupting chemokine het-
eromers in diet-induced atherosclerosis mouse models interferes with 
monocyte recruitment. For example, inhibition of CCL5/CXCL4 het-
eromer formation with MKEY leads to a reduction of lesion area and 
macrophage accumulation in aortic arch, abdominal aorta and aortic 
root [20]. CAN, another peptide-based inhibitor blocked CCL5-CCL17 
heterodimerization thereby abolishing lesion growth in the aortic root 
[13]. Blocking of HNP1-CCL5 interaction by SKY peptide also reduced 
adhesion of monocytes and thus showing atheroprotective effects [10]. 
Preclinical evaluation on interference with chemokine receptors has 
also gained attention. For instance, siRNA treatment targeting CCR2 in 
Apoe− /− mice leads to reduced monocyte accumulation in atheroscle-
rotic plaques [100]. Chrono-pharmacological inhibition of CCL2 by 
using CCR2 antagonist (RS102895) also reduced atherosclerotic lesion 
size [5]. CCR5 inhibitor maraviroc showed protective effects reducing 
by reducing lesional macrophage numbers as well as by diminishing the 
expression of endothelial adhesion molecules and CCL5 in the lesions 
[101]. 
TAK-779 is a non-peptide CCR5/CXCR3 antagonist supplemented to 
Ldlr− /− mice, to antagonize CCR5 and CXCR3 showed inhibition of T cell 
migration to lesions [102] while both, TAK-779 and NBI-74330, another 
CXCR3 antagonist, reduced atherosclerotic plaque formation [103]. 
Preclinical studies on CX3CR1 inhibition involving its antagonist F1 (an 
amino terminus–modified CX3CR1 ligand) and M3 (44-kDa protein 
encoded by the murine gamma herpesvirus 68) shows their negative 
effect on atherosclerotic progression in both Apoe− /− and Ldlr− /− mice 
[104,105]. ACKR3 activation by CCX771 leads to inhibition of the 
binding of CXCL12 to ACKR3 in Apoe− /− mice and resulted in reduced 
macrophage accumulation and decreased lesion size [106]. Fig. 2 has 
depicted all the chemokine targets used in the preclinical studies to 
ameliorate atherosclerosis. 
Pre-clinical studies so far have focused on novel inhibition methods 
like miRNA-based therapy, heterodimer inhibition via peptides and non- 
peptide antagonists. Chemokine ligands like CCL2, CCL5, CCL8 and 
CXCL9 mediate monocyte adhesion to endothelium and thus help in 
atheroprogression. Inhibition of these chemokine ligands by using novel 
miRNA-based therapy ameliorates atherosclerosis. Studies targeting 
chemokine receptors via siRNA treatments and their inhibitors like 
maraviroc also show similar effects. This as a whole shows the relevance 
of chemokine ligands and their receptors targeting in atherosclerosis. 
Various targeting approaches like miRNA, siRNA, chrono- 
pharmacological targeting, peptide and non-peptide antagonist show 
promising atheroprotective effects in mice. With differences in meta-
bolism, immune responses and physical activity between species, 
Fig. 2. Overview of preclinical studies and clinical trials involving targeting of chemokines and their receptors in atherosclerosis. 
Left side of the circle represents preclinical studies. Inhibition of CCL2, CCL5, CCL8 and CXCL9 was performed using miR-146a/-181b. For inhibition of CCL5/CXCL4 
and CCL5/CCL17 heteromers, MKEY peptide and CAN peptide were used, respectively. SKY peptide antagonized the interaction of HNP-1 and CCL5. RS102895 was 
used to inhibit CCL2. Chemokine receptors CCR5, CXCR3 and CX3CR1 were inhibited/antagonized by TAK-779, NBI-74330 and F1/M3 protein, respectively. CCX771 
acts as an agonist to stimulate ACKR3 function. Right side of the circle represents clinical trials. Targeting of chemokine receptors CCR2, CCR5, CXCR2 and CXCR4 
was performed using MLN1202, Maraviroc, AZD5069 and POL6326, respectively. Bindarit was used to antagonize CCL2, CCL8 and CCL7. A non-viral, naked DNA 
plasmid JVS-100 was used as human CXCL12 inhibitor. 
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additional studies are important to analyze if these targets show similar 
effects to target atheroprogression in humans. 
4.2. Clinical studies/trials 
Preclinical studies have demonstrated profound effects of chemo-
kines and their receptors on inflammatory responses related to devel-
opment and progression of atherosclerosis. Some of the above- 
summarized findings have already found their way into clinical 
studies. To delineate ongoing clinical trials in the field of chemokines 
and chemokine receptors in CVD we performed a literature research 
using https://www.clinicaltrialsregister.eu/and https://www.clinicaltr 
ials.gov/websites and could extract the following findings: 
MLN1202 is a monoclonal antibody used in a phase II study to 
analyze the effect of CCR2 inhibition on serum C-reactive protein levels. 
CCR2 antagonism by MLN1202 led to reduction in serum C-reactive 
protein levels in subjects at higher risk of atherosclerosis [85]. However, 
a phase III trial will be required to ascertain the efficacy of MLN1202 in 
atherosclerosis. Another proof of mechanism phase II clinical trial with 
MLN1202 was conducted in patients with stable atherosclerosis and 
examined its effect on arterial inflammation (ClinicalTrials.gov identi-
fier (NCT number): NCT02388971). However, this study was 
withdrawn. 
Maraviroc, a CCR5 antagonist, induced anti-atherosclerotic effect in 
atherosclerosis prone mice and in preliminary data in humans [101]. 
One phase IV clinical study examines effects of maraviroc as a treatment 
of atherosclerotic progression in HIV patients. However, the human 
phase IV study results are pending (ClinicalTrials.gov Identifier: 
NCT03402815). 
Chemokines like CCL2, CCL7 and CCL8 are discussed to regulate 
restenosis processes. Therefore, in a phase II trial, Bindarit was used to 
selectively inhibit CCL2, CCL7 and CCL8 and was evaluated for its 
therapeutic potential to prevent restenosis in patients after undergoing 
percutaneous coronary intervention. This trial showed a trend towards 
Bindarit induced reduction in in-segment late loss, but was not statisti-
cally significant [107]. 
Phase II trial included the safety and efficacy of endocardial dosing of 
JVS-100 (a non-viral, naked DNA plasmid encoding human CXCL12 
inhibitor) to improve cardiac performance in patients with lowest left 
ventricular ejection fraction during high-risk ischemic cardiomyopathy 
[108]. This study failed to demonstrate statistical significance on its 
primary endpoint of improved composite score at 4 months after 
treatment. 
In a randomized controlled trial, CXCR2 antagonist AZD5069 
showed potent inhibition of calcium flux and CD11b expression on 
neutrophils which lead to reversible reduction of neutrophils in the 
circulation [109]. Another ongoing randomized controlled Phase II trial 
(EudraCT number: 2016-000775-24) evaluates if AZD5069 improves 
endothelial function in patients undergoing cutaneous coronary inter-
vention for atherosclerotic coronary disease [110]. The secondary 
endpoint of this trial is to correlate inhibition of CXCR2 to the alteration 
of plaque towards more stable plaques and reduced restenosis. 
Further, a phase II clinical trial (ClinicalTrials.gov Identifier: 
NCT01905475, EudraCT Number: 2012-003229-91) examining the ef-
fect of POL6326, a CXCR4 antagonist on heart function, and healing 
with regard to infarct size in patients with acute myocardial infarction 
has been completed, but with results not yet available. Clinical trials 
with therapeutic agents/molecules targeting chemokines in atheroscle-
rosis are summarized in Fig. 2. 
Considering the amount of pre-clinical studies, relatively few che-
mokine targets are under evaluation in humans. Most of the clinical 
studies are in Phase II, from which, some of them like Bindarit and JVS- 
100 do not show any statistically significant results. Others based on 
antagonists like AZD5069 and POL6326 are either ongoing or completed 
but results are still not available. Only maraviroc which is CCR5 
antagonist, reached in phase IV trails in HIV patients with 
atherosclerosis progression. However, the results from this study is still 
pending. Failure of most of the phase II studies to reach statistical sig-
nificance and their possible withdrawal could be because of the 
complexity of human physiology, underlying comorbidities. Additional 
studies with different approaches to target chemokines without major 
side effects are needed. 
5. Conclusion and future perspectives 
Expression and function of chemokines and their receptors are 
altered in patients with CVD, affecting their conventional role in 
mobilization of immune cells to the sites of inflammation, but also have 
an impact on cellular processes such as cell proliferation, migration, and 
cytokine expression. Moreover, hypoxia, shear stress, and inflammatory 
cytokines influence expression of chemokines and their receptors in 
CVD. The picture is further complicated by age, sex, ethnicity, and ge-
netic variation, as well as differential CVD pathology of these patients, 
not to forget comorbidities like diabetes mellitus or chronic kidney 
which present with altered inflammatory processes different from CVD 
patients without these issues [111]. 
Understanding all these mechanisms that foster and influence 
development of CVD and related comorbidities are of great importance 
and central to be able to take targeted therapeutic approaches to the 
next level. Animal experiments have proven indispensable in uncovering 
mechanisms driving chemokine (receptor) biology in the pathophysi-
ology of atherosclerotic CVD, however, translation of these findings into 
humans is not trivial and demands further effort. Gene expression 
analysis for example reveals interesting and significant changes of che-
mokine and chemokine receptor expression in plaque and blood samples 
of human origin. However, association does not necessarily mirror 
causality therefore mechanistic studies linking cause and consequence 
are needed, a limitation which could be overcome by Mendelian 
randomization analyses. Further, chemokines and chemokine-like mi-
metics may be useful as biomarkers to assess individual atherosclerotic 
burden functioning as imaging tracers (e.g. CXCR4) or as predictors of 
clinical cardiovascular events as (e.g. CCL5 or CCL18). In addition 
(ongoing) clinical trials point at a beneficial role of drugs e.g. inhibiting 
CCR5 or CXCR2 in CVD. In addition, optimization of therapy to address 
circadian rhythmicity may also improve drug efficacy [5]. In parallel, 
nanomedicine-based approaches targeting e.g. vascular adhesion mol-
ecules to deliver therapeutic cargo [112] or downregulation of e.g. CCR2 
expression [100] have gained attention in CVD therapeutic approaches. 
Down this road also a direct, local targeting of chemokines by micro-
RNAs may be promising in reducing atherosclerosis [113]. However, 
spatial as well as temporal aspects of therapeutic application need to be 
considered and careful future evaluation has to show at which costs 
systemic blocking of chemokines or their receptors in CVD versus tissue 
or cell specific targeting approaches may come. Unraveling the che-
mokine network, its diversity, effector functions, and regulation of the 
immune response is essential to develop successful future therapeutic 
strategies. 
Financial support 
This study was supported by Deutsche Forschungsgemeinschaft 
(DFG); SFB1123, project A1 to Y.D. and C⋅W.; by the European Research 
Council (ERC) AdG ◦692,511 PROVASC to C⋅W., by the Swiss Heart 
Foundation project FF20099 to Y.D. and by a grant from the Interdis-
ciplinary Center for Clinical Research within the faculty of Medicine at 
the RWTH Aachen University and NWO-ZonMw Veni (91619053) to E. 
P⋅C.v.d.V. 
Author contributions 
Y.Y: wrote and revised the manuscript with support from E.P.C.v.d. 
V. 
Y. Yan et al.                                                                                                                                                                                                                                     
Atherosclerosis 330 (2021) 95–106
104
M.T: wrote and revised the manuscript with support from E.P.C.v.d. 
V. 
C.W. made critical revisions of the manuscript and provided funding. 
Y.D. Supervised, wrote and revised the manuscript and provided 
funding. 
Declaration of competing interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
References 
[1] G.K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, 
N. Engl. J. Med. 352 (2005) 1685–1695. 
[2] B. Dahlof, Cardiovascular disease risk factors: epidemiology and risk assessment, 
Am. J. Cardiol. 105 (2010) 3A–9A. 
[3] J.W. Griffith, C.L. Sokol, A.D. Luster, Chemokines and chemokine receptors: 
positioning cells for host defense and immunity, Annu. Rev. Immunol. 32 (2014) 
659–702. 
[4] L. Gu, Y. Okada, S.K. Clinton, C. Gerard, G.K. Sukhova, P. Libby, B.J. Rollins, 
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low 
density lipoprotein receptor-deficient mice, Mol. Cell 2 (1998) 275–281. 
[5] C. Winter, C. Silvestre-Roig, A. Ortega-Gomez, P. Lemnitzer, H. Poelman, 
A. Schumski, J. Winter, M. Drechsler, R. de Jong, R. Immler, M. Sperandio, 
M. Hristov, T. Zeller, G.A.F. Nicolaes, C. Weber, J.R. Viola, A. Hidalgo, 
C. Scheiermann, O. Soehnlein, Chrono-pharmacological targeting of the CCL2- 
CCR2 Axis Ameliorates atherosclerosis, Cell Metabol. 28 (2018) 175–182 e5. 
[6] T.H. Schaller, K.A. Batich, C.M. Suryadevara, R. Desai, J.H. Sampson, 
Chemokines as adjuvants for immunotherapy: implications for immune activation 
with CCL3, Expet Rev. Clin. Immunol. 13 (2017) 1049–1060. 
[7] S.C. de Jager, I. Bot, A.O. Kraaijeveld, S.J. Korporaal, M. Bot, P.J. van Santbrink, 
T.J. van Berkel, J. Kuiper, E.A. Biessen, Leukocyte-specific CCL3 deficiency 
inhibits atherosclerotic lesion development by affecting neutrophil accumulation, 
Arterioscler. Thromb. Vasc. Biol. 33 (2013) e75–83. 
[8] L.X. Yang, X.H. Heng, R.W. Guo, Y.K. Si, F. Qi, X.B. Zhou, Atorvastatin inhibits 
the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic 
lesions in atherosclerotic ApoE knockout mice, J. Cardiovasc. Pharmacol. 62 
(2013) 205–211. 
[9] S. Potteaux, C. Combadiere, B. Esposito, C. Lecureuil, H. Ait-Oufella, R. Merval, 
P. Ardouin, A. Tedgui, Z. Mallat, Role of bone marrow-derived CC-chemokine 
receptor 5 in the development of atherosclerosis of low-density lipoprotein 
receptor knockout mice, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1858–1863. 
[10] J.E. Alard, A. Ortega-Gomez, K. Wichapong, D. Bongiovanni, M. Horckmans, R. 
T. Megens, G. Leoni, B. Ferraro, J. Rossaint, N. Paulin, J. Ng, H. Ippel, D. Suylen, 
R. Hinkel, X. Blanchet, F. Gaillard, M. D’Amico, P. von Hundelshausen, 
A. Zarbock, C. Scheiermann, T.M. Hackeng, S. Steffens, C. Kupatt, G.A. Nicolaes, 
C. Weber, O. Soehnlein, Recruitment of classical monocytes can be inhibited by 
disturbing heteromers of neutrophil HNP1 and platelet CCL5, Sci. Transl. Med. 7 
(2015) 317ra196. 
[11] T. Vajen, R.R. Koenen, I. Werner, M. Staudt, D. Projahn, A. Curaj, T.T. Sonmez, 
S. Simsekyilmaz, D. Schumacher, J. Mollmann, T.M. Hackeng, P. 
V. Hundelshausen, C. Weber, E.A. Liehn, Blocking CCL5-CXCL4 heteromerization 
preserves heart function after myocardial infarction by attenuating leukocyte 
recruitment and NETosis, Sci. Rep. 8 (2018) 10647. 
[12] C. Weber, S. Meiler, Y. Doring, M. Koch, M. Drechsler, R.T. Megens, Z. Rowinska, 
K. Bidzhekov, C. Fecher, E. Ribechini, M.A. van Zandvoort, C.J. Binder, I. Jelinek, 
M. Hristov, L. Boon, S. Jung, T. Korn, M.B. Lutz, I. Forster, M. Zenke, 
T. Hieronymus, T. Junt, A. Zernecke, CCL17-expressing dendritic cells drive 
atherosclerosis by restraining regulatory T cell homeostasis in mice, J. Clin. 
Invest. 121 (2011) 2898–2910. 
[13] P. von Hundelshausen, S.M. Agten, V. Eckardt, X. Blanchet, M.M. Schmitt, 
H. Ippel, C. Neideck, K. Bidzhekov, J. Leberzammer, K. Wichapong, A. Faussner, 
M. Drechsler, J. Grommes, J.P. van Geffen, H. Li, A. Ortega-Gomez, R.T. Megens, 
R. Naumann, I. Dijkgraaf, G.A. Nicolaes, Y. Doring, O. Soehnlein, E. Lutgens, J. 
W. Heemskerk, R.R. Koenen, K.H. Mayo, T.M. Hackeng, C. Weber, Chemokine 
interactome mapping enables tailored intervention in acute and chronic 
inflammation, Sci. Transl. Med. 9 (2017). 
[14] S. Yanagihara, E. Komura, J. Nagafune, H. Watarai, Y. Yamaguchi, EBI1/CCR7 is 
a new member of dendritic cell chemokine receptor that is up-regulated upon 
maturation, J. Immunol. 161 (1998) 3096–3102. 
[15] J.K. Damas, C. Smith, E. Oie, B. Fevang, B. Halvorsen, T. Waehre, A. Boullier, 
U. Breland, A. Yndestad, O. Ovchinnikova, A.K. Robertson, W.J. Sandberg, 
J. Kjekshus, K. Tasken, S.S. Froland, L. Gullestad, G.K. Hansson, O. Quehenberger, 
P. Aukrust, Enhanced expression of the homeostatic chemokines CCL19 and 
CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in 
plaque destabilization, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 614–620. 
[16] M. Akhavanpoor, C.A. Gleissner, S. Gorbatsch, A.O. Doesch, H. Akhavanpoor, 
S. Wangler, F. Jahn, F. Lasitschka, H.A. Katus, C. Erbel, CCL19 and CCL21 
modulate the inflammatory milieu in atherosclerotic lesions, Drug Des. Dev. Ther. 
8 (2014) 2359–2371. 
[17] M. Drechsler, R.T. Megens, M. van Zandvoort, C. Weber, O. Soehnlein, 
Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis, 
Circulation 122 (2010) 1837–1845. 
[18] J.C. Copin, R.F. da Silva, R.A. Fraga-Silva, L. Capettini, S. Quintao, S. Lenglet, 
G. Pelli, K. Galan, F. Burger, V. Braunersreuther, K. Schaller, M. Deruaz, A. 
E. Proudfoot, F. Dallegri, N. Stergiopulos, R.A. Santos, Y. Gasche, F. Mach, 
F. Montecucco, Treatment with Evasin-3 reduces atherosclerotic vulnerability for 
ischemic stroke, but not brain injury in mice, J. Cerebr. Blood Flow Metabol. 33 
(2013) 490–498. 
[19] O. Soehnlein, M. Drechsler, Y. Doring, D. Lievens, H. Hartwig, K. Kemmerich, 
A. Ortega-Gomez, M. Mandl, S. Vijayan, D. Projahn, C.D. Garlichs, R.R. Koenen, 
M. Hristov, E. Lutgens, A. Zernecke, C. Weber, Distinct functions of chemokine 
receptor axes in the atherogenic mobilization and recruitment of classical 
monocytes, EMBO Mol. Med. 5 (2013) 471–481. 
[20] R.R. Koenen, P. von Hundelshausen, I.V. Nesmelova, A. Zernecke, E.A. Liehn, 
A. Sarabi, B.K. Kramp, A.M. Piccinini, S.R. Paludan, M.A. Kowalska, A.J. Kungl, T. 
M. Hackeng, K.H. Mayo, C. Weber, Disrupting functional interactions between 
platelet chemokines inhibits atherosclerosis in hyperlipidemic mice, Nat. Med. 15 
(2009) 97–103. 
[21] A. Zernecke, K. Bidzhekov, H. Noels, E. Shagdarsuren, L. Gan, B. Denecke, 
M. Hristov, T. Koppel, M.N. Jahantigh, E. Lutgens, S. Wang, E.N. Olson, 
A. Schober, C. Weber, Delivery of microRNA-126 by apoptotic bodies induces 
CXCL12-dependent vascular protection, Sci. Signal. 2 (2009) ra81. 
[22] S. Akhtar, F. Gremse, F. Kiessling, C. Weber, A. Schober, CXCL12 promotes the 
stabilization of atherosclerotic lesions mediated by smooth muscle progenitor 
cells in Apoe-deficient mice, Arterioscler. Thromb. Vasc. Biol. 33 (2013) 
679–686. 
[23] Y. Doring, E.P.C. van der Vorst, J. Duchene, Y. Jansen, S. Gencer, K. Bidzhekov, 
D. Atzler, D. Santovito, D.J. Rader, D. Saleheen, C. Weber, CXCL12 derived from 
endothelial cells promotes atherosclerosis to drive coronary artery disease, 
Circulation 139 (2019) 1338–1340. 
[24] T. Shimaoka, T. Nakayama, N. Fukumoto, N. Kume, S. Takahashi, J. Yamaguchi, 
M. Minami, K. Hayashida, T. Kita, J. Ohsumi, O. Yoshie, S. Yonehara, Cell surface- 
anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC 
chemokine receptor 6-expressing cells, J. Leukoc. Biol. 75 (2004) 267–274. 
[25] A. Zernecke, C. Weber, Chemokines in atherosclerosis: proceedings resumed, 
Arterioscler. Thromb. Vasc. Biol. 34 (2014) 742–750. 
[26] G.W. Yi, Q.T. Zeng, X.B. Mao, M. Cheng, X.F. Yang, H.T. Liu, Y. Mao, M. Guo, Q. 
W. Ji, Y.C. Zhong, Overexpression of CXCL16 promotes a vulnerable plaque 
phenotype in Apolipoprotein E-Knockout Mice, Cytokine 53 (2011) 320–326. 
[27] S. Potteaux, C. Combadiere, B. Esposito, S. Casanova, R. Merval, P. Ardouin, J. 
L. Gao, P.M. Murphy, A. Tedgui, Z. Mallat, Chemokine receptor CCR1 disruption 
in bone marrow cells enhances atherosclerotic lesion development and 
inflammation in mice, Mol. Med. 11 (2005) 16–20. 
[28] M.D. Majmudar, E.J. Keliher, T. Heidt, F. Leuschner, J. Truelove, B.F. Sena, 
R. Gorbatov, Y. Iwamoto, P. Dutta, G. Wojtkiewicz, G. Courties, M. Sebas, 
A. Borodovsky, K. Fitzgerald, M.W. Nolte, G. Dickneite, J.W. Chen, D. 
G. Anderson, F.K. Swirski, R. Weissleder, M. Nahrendorf, Monocyte-directed 
RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice, 
Circulation 127 (2013) 2038–2046. 
[29] I. Bot, N.V. Ortiz Zacarias, W.E. de Witte, H. de Vries, P.J. van Santbrink, D. van 
der Velden, M.J. Kroner, D.J. van der Berg, D. Stamos, E.C. de Lange, J. Kuiper, 
Ap Ij, L.H. Heitman, A novel CCR2 antagonist inhibits atherogenesis in apoE 
deficient mice by achieving high receptor occupancy, Sci. Rep. 7 (2017) 52. 
[30] V. Braunersreuther, A. Zernecke, C. Arnaud, E.A. Liehn, S. Steffens, 
E. Shagdarsuren, K. Bidzhekov, F. Burger, G. Pelli, B. Luckow, F. Mach, C. Weber, 
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis 
in mice, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 373–379. 
[31] A. Zernecke, E.A. Liehn, J.L. Gao, W.A. Kuziel, P.M. Murphy, C. Weber, 
Deficiency in CCR5 but not CCR1 protects against neointima formation in 
atherosclerosis-prone mice: involvement of IL-10, Blood 107 (2006) 4240–4243. 
[32] C. Clemente, C. Rius, L. Alonso-Herranz, M. Martin-Alonso, A. Pollan, 
E. Camafeita, F. Martinez, R.A. Mota, V. Nunez, C. Rodriguez, M. Seiki, 
J. Martinez-Gonzalez, V. Andres, M. Ricote, A.G. Arroyo, MT4-MMP deficiency 
increases patrolling monocyte recruitment to early lesions and accelerates 
atherosclerosis, Nat. Commun. 9 (2018) 910. 
[33] W. Wan, M.S. Lionakis, Q. Liu, E. Roffe, P.M. Murphy, Genetic deletion of 
chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice, 
Cardiovasc. Res. 97 (2013) 580–588. 
[34] M. Luchtefeld, C. Grothusen, A. Gagalick, K. Jagavelu, H. Schuett, U.J. Tietge, 
O. Pabst, K. Grote, H. Drexler, R. Forster, B. Schieffer, Chemokine receptor 7 
knockout attenuates atherosclerotic plaque development, Circulation 122 (2010) 
1621–1628. 
[35] C.D. Sadik, N.D. Kim, A.D. Luster, Neutrophils cascading their way to 
inflammation, Trends Immunol. 32 (2011) 452–460. 
[36] M.J. Sanz, P. Kubes, Neutrophil-active chemokines in in vivo imaging of 
neutrophil trafficking, Eur. J. Immunol. 42 (2012) 278–283. 
[37] C. Krammer, C. Kontos, M. Dewor, K. Hille, B. Dalla Volta, O. El Bounkari, K. Tas, 
D. Sinitski, M. Brandhofer, R.T.A. Megens, C. Weber, J.R. Schultz, J. Bernhagen, 
A. Kapurniotu, A MIF-derived cyclopeptide that inhibits MIF binding and 
atherogenic signaling via the chemokine receptor CXCR2, Chembiochem 22 (6) 
(2020) 1012–1019. 
[38] A. Rousselle, F. Qadri, L. Leukel, R. Yilmaz, J.F. Fontaine, G. Sihn, M. Bader, 
A. Ahluwalia, J. Duchene, CXCL5 limits macrophage foam cell formation in 
atherosclerosis, J. Clin. Invest. 123 (2013) 1343–1347. 
Y. Yan et al.                                                                                                                                                                                                                                     
Atherosclerosis 330 (2021) 95–106
105
[39] A. Upadhye, P. Srikakulapu, A. Gonen, S. Hendrikx, H.M. Perry, A. Nguyen, 
C. McSkimming, M.A. Marshall, J.C. Garmey, A.M. Taylor, T.P. Bender, 
S. Tsimikas, N.E. Holodick, T.L. Rothstein, J.L. Witztum, C.A. McNamara, 
Diversification and CXCR4-dependent establishment of the bone marrow B-1a cell 
pool governs atheroprotective IgM production linked to human coronary 
atherosclerosis, Circ. Res. 125 (2019) e55–e70. 
[40] Y. Doring, Y. Jansen, I. Cimen, M. Aslani, S. Gencer, L.J.F. Peters, J. Duchene, 
C. Weber, E.P.C. van der Vorst, B-Cell-Specific CXCR4 protects against 
atherosclerosis development and increases plasma IgM levels, Circ. Res. 126 
(2020) 787–788. 
[41] Y. Doring, H. Noels, E.P.C. van der Vorst, C. Neideck, V. Egea, M. Drechsler, 
M. Mandl, L. Pawig, Y. Jansen, K. Schroder, K. Bidzhekov, R.T.A. Megens, 
W. Theelen, B.M. Klinkhammer, P. Boor, L. Schurgers, R. van Gorp, C. Ries, P.J. 
H. Kusters, A. van der Wal, T.M. Hackeng, G. Gabel, R.P. Brandes, O. Soehnlein, 
E. Lutgens, D. Vestweber, D. Teupser, L.M. Holdt, D.J. Rader, D. Saleheen, 
C. Weber, Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity: 
evidence from mouse and human studies, Circulation 136 (2017) 388–403. 
[42] A.A. Puca, A. Carrizzo, C. Spinelli, A. Damato, M. Ambrosio, F. Villa, A. Ferrario, 
A. Maciag, F. Fornai, P. Lenzi, V. Valenti, F. di Nonno, G. Accarino, M. Madonna, 
M. Forte, G. Cali, A. Baragetti, G.D. Norata, A.L. Catapano, M. Cattaneo, R. Izzo, 
V. Trimarco, F. Montella, F. Versaci, A. Auricchio, G. Frati, S. Sciarretta, 
P. Madeddu, E. Ciaglia, C. Vecchione, Single systemic transfer of a human gene 
associated with exceptional longevity halts the progression of atherosclerosis and 
inflammation in ApoE knockout mice through a CXCR4-mediated mechanism, 
Eur. Heart J. 41 (2020) 2487–2497. 
[43] C. Kontos, O. El Bounkari, C. Krammer, D. Sinitski, K. Hille, C. Zan, G. Yan, 
S. Wang, Y. Gao, M. Brandhofer, R.T.A. Megens, A. Hoffmann, J. Pauli, Y. Asare, 
S. Gerra, P. Bourilhon, L. Leng, H.H. Eckstein, W.E. Kempf, J. Pelisek, O. Gokce, 
L. Maegdefessel, R. Bucala, M. Dichgans, C. Weber, A. Kapurniotu, J. Bernhagen, 
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks 
atherogenic inflammation by agonist-specific targeting, Nat. Commun. 11 (2020) 
5981. 
[44] E. Galkina, B.L. Harry, A. Ludwig, E.A. Liehn, J.M. Sanders, A. Bruce, C. Weber, 
K. Ley, CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon- 
gamma production, and macrophage accumulation in the aortic wall, Circulation 
116 (2007) 1801–1811. 
[45] M.J. Butcher, C.I. Wu, T. Waseem, E.V. Galkina, CXCR6 regulates the recruitment 
of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas, Int. 
Immunol. 28 (2016) 255–261. 
[46] Z.B. Hu, Y. Chen, Y.X. Gong, M. Gao, Y. Zhang, G.H. Wang, R.N. Tang, H. Liu, B. 
C. Liu, K.L. Ma, Activation of the CXCL16/CXCR6 pathway by inflammation 
contributes to atherosclerosis in patients with end-stage renal disease, Int. J. Med. 
Sci. 13 (2016) 858–867. 
[47] J.J. Zhou, Y.M. Wang, V.W.S. Lee, G.Y. Zhang, H. Medbury, H. Williams, Y. Wang, 
T.K. Tan, D.C.H. Harris, S.I. Alexander, A.M. Durkan, DEC205-DC targeted DNA 
vaccine against CX3CR1 protects against atherogenesis in mice, PloS One 13 
(2018), e0195657. 
[48] S. Low, H. Wu, K. Jerath, A. Tibolla, B. Fogal, R. Conrad, M. MacDougall, S. Kerr, 
V. Berger, R. Dave, J. Villalona, L. Pantages, J. Ahlberg, H. Li, D. Van Hoorick, 
C. Ververken, J. Broadwater, A. Waterman, S. Singh, R. Kroe-Barrett, VHH 
antibody targeting the chemokine receptor CX3CR1 inhibits progression of 
atherosclerosis, mAbs 12 (2020) 1709322. 
[49] F. Bonacina, E. Martini, M. Svecla, J. Nour, M. Cremonesi, G. Beretta, 
A. Moregola, F. Pellegatta, V. Zampoleri, A.L. Catapano, M. Kallikourdis, G. 
D. Norata, Adoptive transfer of CX3CR1 transduced-T regulatory cells improves 
homing to the atherosclerotic plaques and dampens atherosclerosis progression, 
Cardiovasc. Res. cvaa264 (2020). 
[50] H. Ayari, G. Bricca, Identification of two genes potentially associated in iron- 
heme homeostasis in human carotid plaque using microarray analysis, J. Biosci. 
38 (2013) 311–315. 
[51] S. Hagg, J. Skogsberg, J. Lundstrom, P. Noori, R. Nilsson, H. Zhong, S. Maleki, M. 
M. Shang, B. Brinne, M. Bradshaw, V.B. Bajic, A. Samnegard, A. Silveira, L. 
M. Kaplan, B. Gigante, K. Leander, U. de Faire, S. Rosfors, U. Lockowandt, 
J. Liska, P. Konrad, R. Takolander, A. Franco-Cereceda, E.E. Schadt, T. Ivert, 
A. Hamsten, J. Tegner, J. Bjorkegren, Multi-organ expression profiling uncovers a 
gene module in coronary artery disease involving transendothelial migration of 
leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene 
Expression (STAGE) study, PLoS Genet. 5 (2009), e1000754. 
[52] Y. Doring, H.D. Manthey, M. Drechsler, D. Lievens, R.T. Megens, O. Soehnlein, 
M. Busch, M. Manca, R.R. Koenen, J. Pelisek, M.J. Daemen, E. Lutgens, M. Zenke, 
C.J. Binder, C. Weber, A. Zernecke, Auto-antigenic protein-DNA complexes 
stimulate plasmacytoid dendritic cells to promote atherosclerosis, Circulation 125 
(2012) 1673–1683. 
[53] S. Ravi, R.N. Schuck, E. Hilliard, C.R. Lee, X. Dai, K. Lenhart, M.S. Willis, B. 
C. Jensen, G.A. Stouffer, C. Patterson, J.C. Schisler, Clinical evidence supports a 
protective role for CXCL5 in coronary artery disease, Am. J. Pathol. 187 (2017) 
2895–2911. 
[54] C.C. Huang, D.M. Lloyd-Jones, X. Guo, N.M. Rajamannan, S. Lin, P. Du, Q. Huang, 
L. Hou, K. Liu, Gene expression variation between African Americans and whites 
is associated with coronary artery calcification: the multiethnic study of 
atherosclerosis, Physiol. Genom. 43 (2011) 836–843. 
[55] L.S. Rallidis, E.S. Hamodraka, K. Fountoulaki, G. Moustogiannis, M.G. Zolindaki, 
D.T. Kremastinos, Simvastatin exerts its anti-inflammatory effect in 
hypercholesterolaemic patients by decreasing the serum levels of monocyte 
chemoattractant protein-1, Int. J. Cardiol. 124 (2008) 271–272. 
[56] R. Cortes, C. Ivorra, S. Martinez-Hervas, T. Pedro, V. Gonzalez-Albert, A. Artero, 
V. Adam, A.B. Garcia-Garcia, J.F. Ascaso, J.T. Real, F.J. Chaves, Postprandial 
changes in chemokines related to early atherosclerotic processes in familial 
hypercholesterolemic subjects: a preliminary study, Arch. Med. Res. 47 (2016) 
33–39. 
[57] J. Podolec, G. Kopec, L. Niewiara, M. Komar, B. Guzik, K. Bartus, L. Tomkiewicz- 
Pajak, T.J. Guzik, W. Plazak, K. Zmudka, Chemokine RANTES is increased at early 
stages of coronary artery disease, J. Physiol. Pharmacol. 67 (2016) 321–328. 
[58] J.A. de Lemos, D.A. Morrow, M.S. Sabatine, S.A. Murphy, C.M. Gibson, E. 
M. Antman, C.H. McCabe, C.P. Cannon, E. Braunwald, Association between 
plasma levels of monocyte chemoattractant protein-1 and long-term clinical 
outcomes in patients with acute coronary syndromes, Circulation 107 (2003) 
690–695. 
[59] M. Tajfard, L.A. Latiff, H.R. Rahimi, M. Moohebati, M. Hasanzadeh, A.S. Emrani, 
H. Esmaeily, A. Taghipour, S.R. Mirhafez, G.A. Ferns, M. Mardan-Nik, 
E. Mohammadzadeh, A. Avan, P. Hanachi, M. Ghayour-Mobarhan, Serum 
concentrations of MCP-1 and IL-6 in combination predict the presence of 
coronary artery disease and mortality in subjects undergoing coronary 
angiography, Mol. Cell. Biochem. 435 (2017) 37–45. 
[60] Q. Kong, X. Ma, J.X. Lyu, C. Wang, X.Y. Du, Y.Q. Guan, Plasma RANTES level is 
correlated with cardio-cerebral atherosclerosis burden in patients with ischemic 
cerebrovascular disease, Chronic Dis Transl Med 6 (2020) 46–54. 
[61] Y. Ye, X. Yang, X. Zhao, L. Chen, H. Xie, Y. Zeng, Z. Shen, Z. Fan, Z. Liu, S. Zhang, 
Serum chemokine CCL17/thymus activation and regulated chemokine is 
correlated with coronary artery diseases, Atherosclerosis 238 (2015) 365–369. 
[62] O. Fortunato, G. Spinetti, C. Specchia, E. Cangiano, M. Valgimigli, P. Madeddu, 
Migratory activity of circulating progenitor cells and serum SDF-1alpha predict 
adverse events in patients with myocardial infarction, Cardiovasc. Res. 100 
(2013) 192–200. 
[63] T. Andersen, T. Ueland, T. Ghukasyan Lakic, A. Akerblom, M. Bertilsson, 
P. Aukrust, A.E. Michelsen, S.K. James, R.C. Becker, R.F. Storey, L. Wallentin, 
A. Siegbahn, F.C.-X.-C. Kontny, Ligand 16 is an independent predictor of 
cardiovascular death and morbidity in acute coronary syndromes, Arterioscler. 
Thromb. Vasc. Biol. 39 (2019) 2402–2410. 
[64] A.O. Kraaijeveld, S.C. de Jager, W.J. de Jager, B.J. Prakken, S.R. McColl, 
I. Haspels, H. Putter, T.J. van Berkel, L. Nagelkerken, J.W. Jukema, E.A. Biessen, 
CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/ 
PARC) are specific markers of refractory unstable angina pectoris and are 
transiently raised during severe ischemic symptoms, Circulation 116 (2007) 
1931–1941. 
[65] M.O. Versteylen, M. Manca, I.A. Joosen, D.E. Schmidt, M. Das, L. Hofstra, H. 
J. Crijns, E.A. Biessen, B.L. Kietselaer, CC chemokine ligands in patients 
presenting with stable chest pain: association with atherosclerosis and future 
cardiovascular events, Neth. Heart J. 24 (2016) 722–729. 
[66] J. Li, Y. Guo, X. Luan, T. Qi, D. Li, Y. Chen, X. Ji, Y. Zhang, W. Chen, Independent 
roles of monocyte chemoattractant protein-1, regulated on activation, normal T- 
cell expressed and secreted and fractalkine in the vulnerability of coronary 
atherosclerotic plaques, Circ. J. 76 (2012) 2167–2173. 
[67] I.U. Njerve, S. Solheim, K. Lunde, P. Hoffmann, H. Arnesen, I. Seljeflot, 
Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial 
infarction; no influence of autologous bone marrow derived stem cell injection, 
Cytokine 69 (2014) 131–135. 
[68] M.K. Salem, H.Z. Butt, E. Choke, D. Moore, K. West, T.G. Robinson, R.D. Sayers, 
A.R. Naylor, M.J. Bown, Gene and protein expression of chemokine (C-C-motif) 
ligand 19 is upregulated in unstable carotid atherosclerotic plaques, Eur. J. Vasc. 
Endovasc. Surg. 52 (2016) 427–436. 
[69] D.J. Fitzgerald, L. Roy, F. Catella, G.A. FitzGerald, Platelet activation in unstable 
coronary disease, N. Engl. J. Med. 315 (1986) 983–989. 
[70] F. Cipollone, M. Marini, M. Fazia, B. Pini, A. Iezzi, M. Reale, L. Paloscia, 
G. Materazzo, E. D’Annunzio, P. Conti, F. Chiarelli, F. Cuccurullo, A. Mezzetti, 
Elevated circulating levels of monocyte chemoattractant protein-1 in patients 
with restenosis after coronary angioplasty, Arterioscler. Thromb. Vasc. Biol. 21 
(2001) 327–334. 
[71] N. Inami, S. Nomura, K. Manabe, Y. Kimura, T. Iwasaka, Platelet-derived 
chemokine RANTES may be a sign of restenosis after percutaneous coronary 
intervention in patients with stable angina pectoris, Platelets 17 (2006) 565–570. 
[72] T. Derlin, D.G. Sedding, J. Dutzmann, A. Haghikia, T. Konig, L.C. Napp, 
C. Schutze, N. Owsianski-Hille, H.J. Wester, S. Kropf, J.T. Thackeray, J. 
P. Bankstahl, L. Geworski, T.L. Ross, J. Bauersachs, F.M. Bengel, Imaging of 
chemokine receptor CXCR4 expression in culprit and nonculprit coronary 
atherosclerotic plaque using motion-corrected [(68)Ga]pentixafor PET/CT, Eur. 
J. Nucl. Med. Mol. Imag. 45 (2018) 1934–1944. 
[73] D. Weiberg, J.T. Thackeray, G. Daum, J.M. Sohns, S. Kropf, H.J. Wester, T.L. Ross, 
F.M. Bengel, T. Derlin, Clinical molecular imaging of chemokine receptor CXCR4 
expression in atherosclerotic plaque using (68)Ga-pentixafor PET: correlation 
with cardiovascular risk factors and calcified plaque burden, J. Nucl. Med. 59 
(2018) 266–272. 
[74] M. Kircher, J. Tran-Gia, L. Kemmer, X. Zhang, A. Schirbel, R.A. Werner, A. 
K. Buck, H.J. Wester, M. Hacker, C. Lapa, X. Li, Imaging inflammation in 
atherosclerosis with CXCR4-directed (68)Ga-pentixafor PET/CT: correlation with 
(18)F-fdg PET/CT, J. Nucl. Med. 61 (2020) 751–756. 
[75] L. Wei, J. Petryk, C. Gaudet, M. Kamkar, W. Gan, Y. Duan, T.D. Ruddy, 
Development of an inflammation imaging tracer, (111)In-DOTA-DAPTA, 
targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE(-/-) 
atherosclerosis mouse model, J. Nucl. Cardiol. 26 (2019) 1169–1178. 
Y. Yan et al.                                                                                                                                                                                                                                     
Atherosclerosis 330 (2021) 95–106
106
[76] G. Runmin, J. Jiamei, J. Zhiliang, C. Yonghua, S. Zhizhou, T. Guizhou, 
L. Shuguang, Genetic variation of CXCR4 and risk of coronary artery disease: 
epidemiological study and functional validation of CRISPR/Cas9 system, 
Oncotarget 9 (2018) 14077–14083. 
[77] B.W. Wong, D. Wong, B.M. McManus, Characterization of fractalkine (CX3CL1) 
and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes 
mellitus, and transplant vascular disease, Cardiovasc. Pathol. 11 (2002) 332–338. 
[78] N. Singh, H. Rai, N. Sinha, S. Kumar, C.M. Pandey, S. Agrawal, Association of 
V249I and T280M polymorphisms in the chemokine receptor CX3CR1 gene with 
early onset of coronary artery disease among North Indians, Genet. Test. Mol. 
Biomarkers 16 (2012) 756–760. 
[79] H. Hattori, D. Ito, N. Tanahashi, M. Murata, I. Saito, K. Watanabe, N. Suzuki, 
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic 
cerebrovascular disease, Neurosci. Lett. 374 (2005) 132–135. 
[80] A. Niessner, R. Marculescu, H. Kvakan, A. Haschemi, G. Endler, C.M. Weyand, 
G. Maurer, C. Mannhalter, J. Wojta, O. Wagner, K. Huber, Fractalkine receptor 
polymorphisms V2491 and T280M as genetic risk factors for restenosis, Thromb. 
Haemostasis 94 (2005) 1251–1256. 
[81] S. Apostolakis, V. Amanatidou, E.G. Papadakis, D.A. Spandidos, Genetic diversity 
of CX3CR1 gene and coronary artery disease: new insights through a meta- 
analysis, Atherosclerosis 207 (2009) 8–15. 
[82] D.H. McDermott, A.M. Fong, Q. Yang, J.M. Sechler, L.A. Cupples, M.N. Merrell, P. 
W. Wilson, R.B. D’Agostino, C.J. O’Donnell, D.D. Patel, P.M. Murphy, Chemokine 
receptor mutant CX3CR1-M280 has impaired adhesive function and correlates 
with protection from cardiovascular disease in humans, J. Clin. Invest. 111 
(2003) 1241–1250. 
[83] M.P. Kim, L.M. Wahl, L.R. Yanek, D.M. Becker, L.C. Becker, A monocyte 
chemoattractant protein-1 gene polymorphism is associated with occult ischemia 
in a high-risk asymptomatic population, Atherosclerosis 193 (2007) 366–372. 
[84] R. Kaur, K. Matharoo, P. Arora, A.J. Bhanwer, Association of -2518A>G promoter 
polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene with 
type 2 diabetes and coronary artery disease, Genet. Test. Mol. Biomarkers 17 
(2013) 750–755. 
[85] J. Gilbert, J. Lekstrom-Himes, D. Donaldson, Y. Lee, M. Hu, J. Xu, T. Wyant, 
M. Davidson, M.L.N.S. Group, Effect of CC chemokine receptor 2 CCR2 blockade 
on serum C-reactive protein in individuals at atherosclerotic risk and with a single 
nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter 
region, Am. J. Cardiol. 107 (2011) 906–911. 
[86] K.H. Ting, K.C. Ueng, W.L. Chiang, Y.E. Chou, S.F. Yang, P.H. Wang, Relationship 
of genetic polymorphisms of the chemokine, CCL5, and its receptor, CCR5, with 
coronary artery disease in taiwan, Evid Based Complement Alternat Med 2015 
(2015) 851683. 
[87] C.L. Hyde, A. Macinnes, F.A. Sanders, J.F. Thompson, R.A. Mazzarella, 
O. Faergeman, D.F. van Wijk, L. Wood, M. Lira, S.A. Paciga, Genetic association of 
the CCR5 region with lipid levels in at-risk cardiovascular patients, Circ 
Cardiovasc Genet 3 (2010) 162–168. 
[88] A.R. Afzal, S. Kiechl, Y.P. Daryani, A. Weerasinghe, Y. Zhang, M. Reindl, A. Mayr, 
S. Weger, Q. Xu, J. Willeit, Common CCR5-del32 frameshift mutation associated 
with serum levels of inflammatory markers and cardiovascular disease risk in the 
Bruneck population, Stroke 39 (2008) 1972–1978. 
[89] K. Tse, H. Tse, J. Sidney, A. Sette, K. Ley, T cells in atherosclerosis, Int. Immunol. 
25 (2013) 615–622. 
[90] A. Antonelli, S.M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, P. Fallahi, 
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases, Autoimmun. 
Rev. 13 (2014) 272–280. 
[91] E. Lubberts, Role of T lymphocytes in the development of rheumatoid arthritis. 
Implications for treatment, Curr. Pharmaceut. Des. 21 (2015) 142–146. 
[92] U. Yamashita, E. Kuroda, Regulation of macrophage-derived chemokine (MDC, 
CCL22) production, Crit. Rev. Immunol. 22 (2002) 105–114. 
[93] A. Safa, H.R. Rashidinejad, M. Khalili, S. Dabiri, M. Nemati, M.M. Mohammadi, 
A. Jafarzadeh, Higher circulating levels of chemokines CXCL10, CCL20 and 
CCL22 in patients with ischemic heart disease, Cytokine 83 (2016) 147–157. 
[94] Y. Ye, X. Yang, B. Long, H. Pang, Y. Zhu, S. Zhang, Association between a CCL17 
genetic variant and risk of coronary artery disease in a Chinese han population, 
Circ. J. 82 (2017) 224–231. 
[95] S. Abi-Younes, M. Si-Tahar, A.D. Luster, The CC chemokines MDC and TARC 
induce platelet activation via CCR4, Thromb. Res. 101 (2001) 279–289. 
[96] J. Sjaarda, H. Gerstein, M. Chong, S. Yusuf, D. Meyre, S.S. Anand, S. Hess, G. Pare, 
Blood CSF1 and CXCL12 as causal mediators of coronary artery disease, J. Am. 
Coll. Cardiol. 72 (2018) 300–310. 
[97] M. Desai, J.B. Chauhan, Computational analysis for the determination of 
deleterious nsSNPs in human MTHFR gene, Comput. Biol. Chem. 74 (2018) 
20–30. 
[98] M.A. Lill, M.L. Danielson, Computer-aided drug design platform using PyMOL, 
J. Comput. Aided Mol. Des. 25 (2011) 13–19. 
[99] S. Ma, X.Y. Tian, Y. Zhang, C. Mu, H. Shen, J. Bismuth, H.J. Pownall, Y. Huang, 
W.T. Wong, E-selectin-targeting delivery of microRNAs by microparticles 
ameliorates endothelial inflammation and atherosclerosis, Sci. Rep. 6 (2016) 
22910. 
[100] F. Leuschner, P. Dutta, R. Gorbatov, T.I. Novobrantseva, J.S. Donahoe, 
G. Courties, K.M. Lee, J.I. Kim, J.F. Markmann, B. Marinelli, P. Panizzi, W.W. Lee, 
Y. Iwamoto, S. Milstein, H. Epstein-Barash, W. Cantley, J. Wong, V. Cortez- 
Retamozo, A. Newton, K. Love, P. Libby, M.J. Pittet, F.K. Swirski, V. Koteliansky, 
R. Langer, R. Weissleder, D.G. Anderson, M. Nahrendorf, Therapeutic siRNA 
silencing in inflammatory monocytes in mice, Nat. Biotechnol. 29 (2011) 
1005–1010. 
[101] S. Cipriani, D. Francisci, A. Mencarelli, B. Renga, E. Schiaroli, C. D’Amore, 
F. Baldelli, S. Fiorucci, Efficacy of the CCR5 antagonist maraviroc in reducing 
early, ritonavir-induced atherogenesis and advanced plaque progression in mice, 
Circulation 127 (2013) 2114–2124. 
[102] E.J. van Wanrooij, H. Happe, A.D. Hauer, P. de Vos, T. Imanishi, H. Fujiwara, T. 
J. van Berkel, J. Kuiper, HIV entry inhibitor TAK-779 attenuates atherogenesis in 
low-density lipoprotein receptor-deficient mice, Arterioscler. Thromb. Vasc. Biol. 
25 (2005) 2642–2647. 
[103] E.J. van Wanrooij, S.C. de Jager, T. van Es, P. de Vos, H.L. Birch, D.A. Owen, R. 
J. Watson, E.A. Biessen, G.A. Chapman, T.J. van Berkel, J. Kuiper, CXCR3 
antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL 
receptor-deficient mice, Arterioscler. Thromb. Vasc. Biol. 28 (2008) 251–257. 
[104] L. Poupel, A. Boissonnas, P. Hermand, K. Dorgham, E. Guyon, C. Auvynet, F. 
S. Charles, P. Lesnik, P. Deterre, C. Combadiere, Pharmacological inhibition of the 
chemokine receptor, CX3CR1, reduces atherosclerosis in mice, Arterioscler. 
Thromb. Vasc. Biol. 33 (2013) 2297–2305. 
[105] D. Ravindran, A. Ridiandries, L.Z. Vanags, R. Henriquez, S. Cartland, J.T. Tan, C. 
A. Bursill, Chemokine binding protein ’M3’ limits atherosclerosis in 
apolipoprotein E-/- mice, PloS One 12 (2017), e0173224. 
[106] X. Li, M. Zhu, M.E. Penfold, R.R. Koenen, A. Thiemann, K. Heyll, S. Akhtar, 
S. Koyadan, Z. Wu, F. Gremse, F. Kiessling, M. van Zandvoort, T.J. Schall, 
C. Weber, A. Schober, Activation of CXCR7 limits atherosclerosis and improves 
hyperlipidemia by increasing cholesterol uptake in adipose tissue, Circulation 129 
(2014) 1244–1253. 
[107] A. Colombo, S. Basavarajaiah, U. Limbruno, A. Picchi, C. Lettieri, M. Valgimigli, 
A. Sciahbasi, F. Prati, M. Calabresi, D. Pierucci, A. Guglielmotti, A double-blind 
randomised study to evaluate the efficacy and safety of bindarit in preventing 
coronary stent restenosis, EuroIntervention 12 (2016) e1385–e1394. 
[108] E.S. Chung, L. Miller, A.N. Patel, R.D. Anderson, F.O. Mendelsohn, J. Traverse, K. 
H. Silver, J. Shin, G. Ewald, M.J. Farr, S. Anwaruddin, F. Plat, S.J. Fisher, A. 
T. AuWerter, J.M. Pastore, R. Aras, M.S. Penn, Changes in ventricular remodelling 
and clinical status during the year following a single administration of stromal 
cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure 
patients: the STOP-HF randomized Phase II trial, Eur. Heart J. 36 (2015) 
2228–2238. 
[109] S. Jurcevic, C. Humfrey, M. Uddin, S. Warrington, B. Larsson, C. Keen, The effect 
of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and 
innate immune functions, Br. J. Clin. Pharmacol. 80 (2015) 1324–1336. 
[110] J.P. Joseph, E. Reyes, J. Guzman, J. O’Doherty, H. McConkey, S. Arri, R. Kakkar, 
N. Beckley, A. Douiri, S.F. Barrington, S.R. Redwood, A. Ferro, CXCR2 Inhibition - 
a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol 
for a randomised controlled trial, Trials 18 (2017) 473. 
[111] N. Marx, H. Noels, J. Jankowski, J. Floege, D. Fliser, M. Bohm, Mechanisms of 
cardiovascular complications in chronic kidney disease: research focus of the 
transregional research consortium SFB TRR219 of the university hospital aachen 
(RWTH) and the saarland university, Clin. Res. Cardiol. 107 (2018) 120–126. 
[112] A. Nakhlband, M. Eskandani, Y. Omidi, N. Saeedi, S. Ghaffari, J. Barar, A. Garjani, 
Combating atherosclerosis with targeted nanomedicines: recent advances and 
future prospective, Bioimpacts 8 (2018) 59–75. 
[113] P. Hartmann, A. Schober, C. Weber, Chemokines and microRNAs in 
atherosclerosis, Cell. Mol. Life Sci. 72 (2015) 3253–3266. 
Y. Yan et al.                                                                                                                                                                                                                                     
